Stocks and Investing
Stocks and Investing
Mon, February 25, 2019
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Fri, February 22, 2019
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Thu, February 21, 2019
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Thomas Shrader Downgraded (BIIB) to Hold and Decreased Target to $346 on, Feb 21st, 2019
Thomas Shrader of Stifel, Downgraded "Biogen Inc." (BIIB) to Hold and Decreased Target from $397 to $346 on, Feb 21st, 2019.
Thomas has made no other calls on BIIB in the last 4 months.
There are 2 other peers that have a rating on BIIB. Out of the 2 peers that are also analyzing BIIB, 0 agree with Thomas's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Thomas
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $401 on, Wednesday, December 19th, 2018
- Cory Kasimov of "JP Morgan" Maintained at Buy with Decreased Target to $436 on, Wednesday, October 24th, 2018
Contributing Sources